ATF4 and hepatocellular carcinoma: Sorafenib, which is thought to resensitize cells to itself, may promote ZFAS1 activation by activating the PERK/ATF4 pathway and inhibiting PERK signaling in resistant HCC cells (Lin et al., 2021a).